Search

Displaying results 751 - 760 of 4591 in total
  1. Drug

    Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16727
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. … The final purified antivenin product is obtained by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques.

  3. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion

  4. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.

  5. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    by a reduced number of mature neutrophils and lymphocytes. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.

  6. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. … [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells.

  7. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle". … The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation

  8. Drug

    Vitamin D

    go.drugbank.com/drugs/DB11094
    ApprovedInvestigationalNutraceuticalVet approved

    Vitamin D3 and D2 require hydroxylation in order to become biologically active in the human body. … Since vitamin D can be endogenously synthesized in adequate amounts by most mammals exposed to sufficient quantities of sunlight, vitamin D functions like a hormone on vitamin D receptors to regulate calcium

  9. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

    Categories: Drug Delivery Systems
  10. Drug

    Epinephrine

    go.drugbank.com/drugs/DB00668
    ApprovedInvestigationalVet approved

    Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection. … Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions.